

Ref No.: ZLL/CS/BSE/NSE

Date: 03.12.2025

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
-----------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Sub: Press Release for CDSCO approval for Naproxen + Esomeprazole Capsules

Please find enclosed herewith the Press Release relating to Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/ 20mg) received from the Central Drugs Standard Control Organisation (CDSCO) - Directorate General of Health Services to the company.

Request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl.: as above

ZIM LABORATORIES LIMITED

PRESS RELEASE

ZIM Laboratories Limited Receives Approval from Central Drugs Standard Control Organization (CDSCO) – Directorate General of Health Services for Naproxen + Esomeprazole Capsules

Nagpur, India - December 03, 2025

Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)

ZIM Laboratories Limited (the Company) is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The Company has state-of-the-art in-house R&D capabilities to offer innovative drug delivery solutions using proprietary technology platforms, aiming to enhance patient convenience and treatment adherence. ZIM Laboratories Limited is listed on the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange (BSE) Limited.

The company is pleased to announce that it has received permission from the Indian Central Drugs Standard Control Organization (CDSCO) for its novel Fixed Dose Combination formulation:

Naproxen Delayed Release and Esomeprazole Capsules (375 mg/500 mg + 20 mg/20 mg)

This product has been developed using ZIM's proprietary drug delivery systems, comprising:

Naproxen Delayed-Release Minitablets, and Esomeprazole Pellets, filled together in a single hard gelatin capsule—offering a differentiated and patient-friendly delivery platform and is part of our New Innovative Product (NIP) pipeline.

Therapeutic Indication

The FDC is indicated in adults for:

Symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
Reducing the risk of NSAID-associated gastric and duodenal ulcers

Strategic Significance

This approval strengthens ZIM's presence in the pain management and gastro-protective therapeutic areas. ZIM has already signed a commercial supply agreement with an Indian pharmaceutical company for this product and is working toward commercial launch in India in FY 2026-27 (FY27).

The approval also reinforces ZIM's strategy of developing innovative, differentiated generics leveraging advanced formulation technologies.
